Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
p38-α MAPK-IN-1
Cat. No.:
OB0225LY-0468
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
p38-α MAPK-IN-1 is a selective p38 MAPK inhibitor that interferes with cellular stress responses.
Synonym:
443913-15-3; p38-alpha MAPK-IN-1; p38-|A MAPK-IN-1; p38-(alpha) MAPK-IN-1; 1-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-ylethoxy)phenyl]urea; 1-[5-tert-Butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)phenyl]urea; 1-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)phenyl)urea
CAS No.:
443913-15-3
Compound CID:
10972838
Formula:
C27H35N5O3
Formula Weight:
477.6
Specification
Relative Density:
1.19 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
p38-α MAPK-IN-1 can be used to study the mechanisms of cellular stress and inflammatory responses or play an important role in neurodegenerative disease research.
Library Information
Targets:
Serine/Threonine kinases
Receptors:
p38α
Pathways:
MAPK; Autophagy
Plate Number:
AOCL-7
Plate Location:
a6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
100 mg/mL; 209.38 mM
Solubility:
Insoluble in water.
